Immunoglobulin-induced hemolysis, splenomegaly and inflammation in patients with antibody deficiencies

References

• Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the primary immunodeficiency committee of the American academy of allergy, asthma and immunology. J Allergy Clin Immunol. 2006;117:S525–S553.
   PubMed Web of Science ®Google Scholar
• Roifman CM, Lederman HM, Lavi S, et al. Benefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary disease. Am J Med. 1985;7:9171–9174.
   Google Scholar
• Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. Cooperative group for the study of immunoglobulin in chronic lymphocytic leukemia. N Engl J Med. 1988;319:902–907.
   PubMed Web of Science ®Google Scholar
• Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin North Am. 2008;28:413–437.
   PubMed Web of Science ®Google Scholar
• Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol. 2004;112:1–7.
   PubMed Web of Science ®Google Scholar
• Milito C, Pulvirenti F, Pesce AM, et al. Adequate patient’s outcome achieved with short immunoglobulin replacement intervals in severe antibody deficiencies. J Clin Immunol. 2014;34:813–819.
   PubMed Web of Science ®Google Scholar
• Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barrésyndrome. Plasma exchange/Sandoglobulin Guillain-Barré syndrome trial group. Lancet. 1997;349:225–230.
   PubMed Web of Science ®Google Scholar
• Imbach P, Barandun S, d’Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1:1228–1231.
   PubMed Web of Science ®Google Scholar
• Burns JC, Franco A. The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease. Expert Rev Clin Immunol [Internet]. 2015;11:819–825. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/03/WC500078472.pdf http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/07/WC500190211.pdf
   PubMed Web of Science ®Google Scholar
• [EMA] European Medicine Agency. Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg) [Internet]. Edition 2010. [cited 2015 Feb]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/03/WC500078472.pdf
   Google Scholar
• [EMA] European Medicine Agency. Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg) [Internet]. Edition 2015. [cited 2015 Feb]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/07/WC500190211.pdf
   Google Scholar
• Cherin P, Herson S, Wechsler B, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med. 1991;91:162–168.
   PubMed Web of Science ®Google Scholar
• Sewell WA, Jolles S. Immunomodulatory action of intravenous immunoglobulin. Immunology. 2002;107:387–393.
   PubMed Web of Science ®Google Scholar
• Baxley A, Akhtari M. Hematologic toxicities associated with intravenous immunoglobulin therapy. Int Immunopharmacol. 2011;11:1663–1667.
   PubMed Web of Science ®Google Scholar
• Quinti I, Coluzzi S, Pulvirenti F, et al. Polyvalent immunoglobulins: challenges and perspectives. Blood Transfus. 2013;11(Suppl 4):s40–s44.
   PubMed Web of Science ®Google Scholar
• Daw Z, Padmore R, Neurath D, et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion. 2008;48:1598–1601.
   PubMed Web of Science ®Google Scholar
• Desborough MJ, Miller J, Thorpe SJ, et al. Intravenous immunoglobulin-induced haemolysis: a case report and review of the literature. Transfus Med. 2014;24:219–226.
   PubMed Web of Science ®Google Scholar
• Kessary-Shoham H, Levy Y, Shoenfeld Y, et al. In vivo administration of intravenous immunoglobulin (IVIg) can lead to enhanced erythrocyte sequestration. J Autoimmun. 1999;13:129–135.
   PubMed Web of Science ®Google Scholar
• Gordon DJ, Sloan SR, De Jong JL. A pediatric case series of acute hemolysis after administration of intravenous immunoglobulin. Am J Hematol. 2009;84:771–772.
   PubMed Web of Science ®Google Scholar
• Kahwaji J, Barker E, Pepkowitz S, et al. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Clin J Am Soc Nephrol. 2009;4:1993–1997.
   PubMed Web of Science ®Google Scholar
• Pintova S, Bhardwaj AS. Aledort LM IVIG–a hemolytic culprit. N Engl J Med. 2012;10:974–976.
   Web of Science ®Google Scholar
• Wilson JR, Bhoopalam H, Fisher M. Hemolytic anemia associated with intravenous immunoglobulin. Muscle Nerve. 1997;20:1142–1145.
   PubMed Web of Science ®Google Scholar
• Quinti I, Pulvirenti F, Milito C, et al. Hemolysis in patients with antibody deficiencies on immunoglobulin replacement treatment. Transfusion. 2015;55:1067–1074.
   PubMed Web of Science ®Google Scholar
• Sewell WA, Kerr J, Behr-Gross M-E, et al. Working group European consensus proposal for immunoglobulin therapies. Eur J Immunol. 2014;44:2207–2214.
   PubMed Web of Science ®Google Scholar
• Romberg V Effects of the manufacturing process on anti-A titers in IVIG. Presentation at workshop “Strategies to Address Hemolytic Complications of Immune Globulin Infusions” US Food and Drug Administration; 2014 Jan 29; Bethesda, MD, USA.
   Google Scholar
• Bellac CL, Polatti D, Hottiger T, et al. Anti-A and anti-B haemagglutinin levels in intravenous immunoglobulins: are they on the rise? A comparison of four different analysis methods and six products. Biologicals. 2014;42:57–64.
   PubMed Web of Science ®Google Scholar
• Taylor E. Intravenous immune globulin (IVIG): hemolytic reactions. Can Adverse React Newsl. 2009;19:1–3.
   Google Scholar
• Padmore RF. Hemolysis upon intravenous immunoglobulin transfusion. Transfus Apher Sci. 2012;46:93–96.
   PubMed Web of Science ®Google Scholar
• Berg R, Shebl A, Kimber MC, et al. Hemolytic events associated with intravenous immune globulin therapy: a qualitative analysis of 263 cases reported to four manufacturers between 2003 and 2012. Transfusion. 2015;55(Suppl 2):S36–S46.
   PubMed Web of Science ®Google Scholar
• Cherin P, Marie I, Michallet M, et al. Management of adverse events in the treatment of patients with immunoglobulin therapy: A review of evidence. Autoimmun Rev. 2016;15:71–81.
   Web of Science ®Google Scholar
• APIIEG. Consensus raccomandations for use of immunoglobulin replacement therapy in immune deficiency. 2008. [cited 2015 Feb]. Available from http://www.apiieg.org/.
   Google Scholar
• Buchta C, Macher M, Höcker P. Potential approaches to prevent uncommon hemolytic side effects of AB0 antibodies in plasma derivatives. Biologicals. 2005;33:41–48.
   PubMed Web of Science ®Google Scholar
• Garratty G. What is the mechanism for acute hemolysis occurring in some patients after intravenous anti-D therapy for immune thrombocytopenic purpura?. Transfusion. 2009;49:1026–1031.
   PubMed Web of Science ®Google Scholar
• Shoham-Kessary H, Naot Y, Gershon H. Immune complex-like moieties in immunoglobulin for intravenous use (IVIg) bind complement and enhance phagocytosis of human erythrocytes. Clin Exp Immunol. 1998;113:77–84.
   PubMed Web of Science ®Google Scholar
• Basta M. Ambivalent effect of immunoglobulins on the complement system: activation versus inhibition. Mol Immunol. 2008;45:4073–4407.
   PubMed Web of Science ®Google Scholar
• Späth PJ, Granata G, La Marra F, et al. On the dark side of therapies with immunoglobulin concentrates: the adverse events. Front Immunol. 2015;6:11.
   PubMed Web of Science ®Google Scholar
• Lamoureux J, Aubin E, Lemieux R. Autoantibodies purified from therapeutic preparations of intravenous immunoglobulins (IVIg) induce the formation of autoimmune complexes in normal human serum: a role in the in vivo mechanisms of action of IVIg?. Int Immunol. 2004;16:929–936.
   PubMed Web of Science ®Google Scholar
• Zimring JC. Do immune complexes play a role in hemolytic sequelae of intravenous immune globulin? Transfusion. 2015;55(Suppl 2):S86–S89.
   Google Scholar
• Pendergrast J, Willie-Ramharack K, Sampson L, et al. The role of inflammation in intravenous immune globulin-mediated hemolysis. Transfusion. 2015;55(Suppl 2):S65–S73.
   PubMed Web of Science ®Google Scholar
• Attanasio, Shumilina E, Hermle T, et al. Stimulation of eryptosis by anti-A IgG antibodies. Cell Physiol Biochem. 2007;20:591–600.
   PubMed Web of Science ®Google Scholar
• Mohamed M, Bates G, Eastley B. Massive intravascular haemolysis after high dose intravenous immunoglobulin therapy. Br J Haematol. 2013;160:570–10.
   PubMed Web of Science ®Google Scholar
• Berard R, Whittemore B, Scuccimarri R. Hemolytic anemia following intravenous immunoglobulin therapy in patients treated for Kawasaki disease: a report of 4 cases. Pediatr Rheumatol Online J. 2012;10:10.
   PubMed Web of Science ®Google Scholar
• Michelis FV, Branch DR, Scovell I, et al. Acute hemolysis after intravenous immunoglobulin amid host factors of ABO-mismatched bone marrow transplantation, inflammation, and activated mononuclear phagocytes. Transfusion. 2014;54:681–690.
   PubMed Web of Science ®Google Scholar
• Morgan S, Sorensen P, Vercellotti G, et al. Hemolysis after treatment with intravenous immunoglobulin due to anti-A. Transfus Med. 2011;21:267–270.
   PubMed Web of Science ®Google Scholar
• Singh-Grewal D, Kemp A, Wong M. A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions. Arch Dis Child. 2006;91:651–654.
   PubMed Web of Science ®Google Scholar
• Report of the FDA meeting on strategies to address hemolytic complications of Immune Globulin Infusions. Washington, DC: US FDA; 2014.
   Google Scholar
• Brox AG, Cournoyer D, Sternbach M, et al. Hemolytic anemia following intravenous gamma globulin administration. Am J Med. 1987;82(3 Spec No):633–635.
   PubMed Web of Science ®Google Scholar
• Thorpe SJ, Fox BJ, Dolman CD, et al. Anti-A and anti-B activity in batches of different intravenous immunoglobulin products determined using a direct haemagglutination method. Biologicals. 2005;33:111–116.
   PubMed Web of Science ®Google Scholar
• Thorpe SJ, Fox B, Sharp G, et al. International collaborative study to evaluate candidate reference reagents to standardize haemagglutination testing for anti-A and anti-B in normal intravenous immunoglobulin products. Vox Sang. 2009;97:160–168.
   PubMed Web of Science ®Google Scholar
• European Directorate for the Quality of Medicines and Healthcare. Anti-A and Anti-B Haemagglutinins. 7th General Chapter 2.6.20 ed European Pharmacopoeia. Strasbourg: Council of Europe; 2011.
   Google Scholar
• European Directorate for the Quality of Medicines and Healthcare. Test for Anti-D Antibodies in Human Immunoglobulin. 7th General Chapter 2.6.26 ed European Pharmacopoeia. Strasbourg: Council of Europe; 2011. 3546 p.
   Google Scholar
• Thorpe SJ. Specifications for anti-A and anti-B in intravenous immunoglobulin: history and rationale. Transfusion. 2015;55(Suppl 2):S80–S85.
   PubMed Web of Science ®Google Scholar
• Hudson KE, Lin E, Hendrickson JE, et al., et al. Regulation of primary alloantibody response through antecedent exposure to a microbial T-cell epitope. Blood. 2010;115:3989–3996.
   PubMed Web of Science ®Google Scholar
• Schroeder HW Jr, Dougherty CJ. Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients. Infection. 2012;40:601–611.
   PubMed Web of Science ®Google Scholar
• Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol. 2006;6:535–542.
   PubMed Web of Science ®Google Scholar
• Geha R, Notarangelo LD, Casanova JL, et al. International union of immunological societies primary immunodeficiency diseases classification committee. Primary immunodeficiency diseases: an update from the international union of immunological societies primary immunodeficiency diseases classification committee. J Allergy Clin Immunol. 2007;120:776–794.
   PubMed Web of Science ®Google Scholar
• Aygun B, Padmanabhan S, Paley C, et al. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion. 2002;421:37–43.
   Web of Science ®Google Scholar
• Chapel H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008;112:277–286.
   PubMed Web of Science ®Google Scholar
• Agarwal S, Cunningham-Rundles C. Autoimmunity in common variable immunodeficiency. Curr Allergy Asthma Rep. 2009;9:347–352.
   Google Scholar
• Gathmann B, Mahlaoui N, CEREDIH, et al.. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol. 2014;134:116–126.
   PubMed Web of Science ®Google Scholar
• Morimoto Y, Routes JM. Granulomatous disease in common variable immunodeficiency. Curr Allergy Asthma Rep. 2005;5:370–375.
   PubMed Web of Science ®Google Scholar
• Wehr C, Kivioja T, Schmitt C, et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood. 2008;111:77–85.
   PubMed Web of Science ®Google Scholar
• Warnatz K, Denz A, Dräger R, et al. Severe deficiency of switched memory B cells (CD27(+)IgM(-)IgD(-)) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease. Blood. 2002;99:1544–1551.
   PubMed Web of Science ®Google Scholar
• Fevang B, Yndestad A, Damås JK, et al. Chemokines and common variable immunodeficiency; possible contribution of CCL19, CCL21 and CCR7 to immune dysregulation. Clin Exp Immunol. 2009;158:237–245.
   PubMed Web of Science ®Google Scholar
• Taraldsrud E, Fevang B, Aukrust P, et al. Common variable immunodeficiency revisited: normal generation of naturally occurring dendritic cells that respond to Toll-like receptors 7 and 9. Clin Exp Immunol. 2014;175:439–448.
   PubMed Web of Science ®Google Scholar
• Mackay F, Silveira PA, Brink R. The EUROclass trial: defining subgroups in B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. Curr Opin Immunol. 2007;19:327–336.
   PubMed Web of Science ®Google Scholar
• Yu GP, Chiang D, Song SJ, et al. Regulatory T cell dysfunction in subjects with common variable immunodeficiency complicated by autoimmune disease. Clin Immunol. 2009;131:240–253.
   PubMed Web of Science ®Google Scholar
• Zhang L, Radigan L, Salzer U, et al. Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in common variable immunodeficiency: clinical and immunologic outcomes in heterozygotes. J Allergy Clin Immunol. 2007;120:1178–1185.
   PubMed Web of Science ®Google Scholar
• Barbosa RR, Silva SL, Silva SP, et al. Reduced BAFF-R and increased TACI expression in common variable immunodeficiency. Clin Immunol. 2014;34:573–583.
   Web of Science ®Google Scholar
• Quinti I, Soresina A, Spadaro G, et al. Italian primary immunodeficiency network. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immunol. 2007;27:308–316.
   PubMed Web of Science ®Google Scholar
• Wong GK, Goldacker S, Winterhalter C, et al. Outcomes of splenectomy in patients with common variable immunodeficiency (CVID): a survey of 45 patients. Clin Exp Immunol. 2012;172:63–72.
   Web of Science ®Google Scholar
• Davenport R. Cytokines and erythrocyte incompatibility. Curr Opin Hematol. 1994;6:452–456.
   Google Scholar
• Davenport RD, Burdick M, Strieter RM, et al. Monocyte chemoattractant protein production in red cell incompatibility. Transfusion. 1994;34:16–19.
   PubMed Web of Science ®Google Scholar
• Mollnes TE, Høgåsen K, De Carolis C, et al. High-dose intravenous immunoglobulin treatment activates complement in vivo. Scand J Immunol. 1998;3:312–317.
   Google Scholar
• Pulvirenti F, Pentassuglio I, Milito C, et al. Idiopathic non cirrhotic portal hypertension and spleno-portal axis abnormalities in patients with severe primary antibody deficiencies. J Immunol Res. 2014;2014:672458.
   PubMed Web of Science ®Google Scholar
• Dhainaut F, Guillaumat PO, Dib H, et al. In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations. Vox Sang. 2013;104:115–126.
   PubMed Web of Science ®Google Scholar
• Siani B, Willimann K, Wymann S, et al. Isoagglutinin reduction in human immunoglobulin products by donor screening. Biol Ther. 2014;4:15–26.
   PubMedGoogle Scholar
• Höfferer L IgG product development isoagglutinin reduction measures. Oral presentation, International Plasma Protein Congress Vienna: Plasma Protein Therapeutics Association; 2014.
   Google Scholar
• Hoefferer L, Glauser I, Gaida A, et al. Isoagglutinin reduction by a dedicated immunoaffinity chromatography step in the manufacturing process of human immunoglobulin products. Transfusion. 2015;55(Suppl 2):S117–S121.
   PubMed Web of Science ®Google Scholar